JCM
RPTX

JS Capital Management’s Repare Therapeutics RPTX Stock Holding History

JS Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,500
Closed -$230K – 99
2021
Q1 		$230K Buy
+7,500
New +$255K 0.01% 120

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JS Capital Management's RPTX Position: Q2 2021 in Review

JS Capital Management sold out of Repare Therapeutics (RPTX) in Q2 2021, closing a stake of 7,500 shares — an estimated $230K sold.

JS Capital Management first reported a position in RPTX in Q1 2021 and held it in 1 quarter. The position peaked at $230K in Q1 2021. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2021.

  • JS Capital Management reported no remaining Repare Therapeutics position as of Q2 2021 after selling out during the quarter.
  • JS Capital Management sold 7,500 Repare Therapeutics shares in Q2 2021, an estimated $230K.
  • JS Capital Management first reported a position in Repare Therapeutics in Q1 2021 and held it in 1 quarter.
  • JS Capital Management's Repare Therapeutics position peaked at $230K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2021.

Based on JS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.